Bronchoalveolar lavage fluid of lung cancer patients: Mapping the uncharted waters using proteomics technology

Lung Cancer

Volumn 72, Issue 1, 2011, Pages 136-138

  Oumeraci, Tonio ^a   Schmidt, Bernd ^b   Wolf, Thomas ^a,c   Zapatka, Marc ^c   Pich, Andreas ^a   Brors, Benedikt ^c   Eils, Roland ^c,d   Fleischhacker, Michael ^e   Schlegelberger, Brigitte ^a   von Neuhoff, Nils ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bioinformatics; Biomarkers; Bronchoalveolar lavage fluid; MALDI TOF mass spectrometry; NSCLC; Proteomics

Indexed keywords

PROTEOME;

BLOOD LEVEL; HUMAN; LETTER; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEOMICS;

BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MASS SPECTROMETRY; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952184685     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.015     Document Type: Letter

References (10)

1. Hammerschmidt S., Wirtz H. Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int 2009, 106:809-818. quiz 819-20.
2. Marko-Varga G., Ogiwara A., Nishimura T., Kawamura T., Fujii K., Kawakami T., et al. Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res 2007, 6:2925-2935.
3. Chenau J., Michelland S., de Fraipont F., Josserand V., Coll J.L., Favrot M.C., et al. The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res 2009, 8:4579-4591.
4. Kähler D., Alexander C., Schultz H., Abdullah M., Branscheid D., Lindner B., et al. Proteomics out of the archive: two-dimensional electrophoresis and mass spectrometry using HOPE-fixed, paraffin-embedded tissues. J Histochem Cytochem 2010, 58:221-228.
5. Schmidt B., Liebenberg V., Dietrich D., Schlegel T., Kneip C., Seegebarth A., et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010, 10:600.
6. Doroshow J.H. Targeting EGFR in non-small-cell lung cancer. N Engl J Med 2005, 353:200-202.
7. Dempke W.C., Suto T., Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67:257-274.
8. Herth F.J., Eberhardt R. Flexible bronchoscopy and its role in the staging of non-small cell lung cancer. Clin Chest Med 2010, 31:87-100.
9. Lorenz E., Muhlebach M.S., Tessier P.A., Alexis N.E., Duncan Hite R., Seeds M.C., et al. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008, 102:567-573.
10. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008, 181:4666-4675.